Cases in Infectious Disease: Anti-Vaccine Concerns, Measles, and New Vaccine Recommendations (Recorded at Pri-Med Midwest)
Over the past 20 years, there has been push back from patients about vaccines. This has been driven by concerns about vaccine safety promoted by the media, celebrities, and (now retracted) scientific reviews. As a result, there have been numerous outbreaks of rare, vaccine preventable infections. There has been a resurgence of mumps, pertussis and respiratory syncytial virus infections. Currently the United States is facing growing numbers of measles cases. These infections put the most vulnerable patients at risk of serious morbidity and mortality. All clinicians should understand what is true and untrue about the anti-vaccine controversy and how to discuss the benefits and risks of vaccination with their patients. Clinicians should also be aware of the most updated adult vaccine recommendations by the CDC and ACIP and ensure their patients are vaccinated properly. Given the recent resurgence of measles, clinicians should also be able to recognize a case of measles, how to diagnose and care for patients with suspected measles, and how to report a case to their local public health department.
The following relevant financial relationships have been disclosed by faculty:
Michael Angarone, DO
Speaker's Bureau for Allergan Pharmaceuticals
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
pmiCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.